Edwards Plans To Keep ‘First-Mover’ Advantage In TAVI Against Emerging Competition
This article was originally published in The Gray Sheet
Executive Summary
Edwards is counting on the Sapien XT valve, which will likely earn FDA approval soon, to compete with Medtronic’s recently approved CoreValve in the U.S, while in Europe the company is working quickly to upgrade customers to Sapien 3.